Laboratoires Pierre Fabre SA - Company Profile
Powered by 
All the sales intelligence you need on Laboratoires Pierre Fabre SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Laboratoires Pierre Fabre SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Laboratoires Pierre Fabre SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Laboratoires Pierre Fabre SA (Pierre Fabre), a subsidiary of Pierre Fabre Foundation, is a pharmaceutical company that develops and distributes complementary products, over-the-counter drugs, prescription drugs, natural and consumer health care products, and dermo-cosmetics. The company provides treatment for oncology, dermatology, rare diseases, chronic diseases, smoking cessation, consumer healthcare, natural health, and oral health. Pierre Fabre offers its products to customers through healthcare professionals and a network of pharmacies and drugstores under the brands Eau Thermale Avene, Ducray, Klorane, A-Derma, Rene Furterer, Darrow, Dexeryl, among others. It operates in various countries globally, including China, Germany, Spain, Italy, the US, Mexico, Brazil, and Poland, among others. Pierre Fabre is headquartered in Paris, Ile-de-France, France.
Headquarters
France
Address
Parc Industriel de La Chartreuse, Castres, 81100
Website
www.pierre-fabre.com
Telephone
33 563 623850
No of Employees
10,000
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$3.3B
Laboratoires Pierre Fabre SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Dermatology | A-Derma |
| Oncology | Dexeryl |
| Cell Therapy | Ducray |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In June, the company acquired the worldwide rights for PFL-721 and PFL-241 from Antares Therapeutics, Inc. |
| 2024 | Research and Development | In October, the company and Scorpion Therapeutics announced a new Phase I/II clinical trial for an innovative treatment in oncology. |
| 2024 | Regulatory Approval | In July, the company received approval from the UK Medicines and Healthcare Products Regulatory Agency for vibegron (Obgemsa) to treat overactive bladder syndrome symptoms in adults. |
Competitor Comparison
| Key Parameters | Laboratoires Pierre Fabre SA | Bristol-Myers Squibb Co | The Body Shop International Ltd | Laboratoires Mayoly Spindler SAS | Beaufour Ipsen Pharma |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | United Kingdom | France | Argentina |
| City | Castres | Princeton | Littlehampton | Chatou | Buenos Aires |
| State/Province | - | New Jersey | England | Ile-de-France | Ciudad Autonoma De Buenos Aires |
| No. of Employees | 10,000 | 32,500 | - | 2,200 | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Herve Hoppenot | Chairman | Executive Board | 2026 | - |
| Eric Ducournau | Chief Executive Officer | Executive Board | 2018 | - |
| Eric Gouy | Chief Financial Officer; Senior Vice President - Administrative, Finance and Legal | Senior Management | - | - |
| Vincent Huraux | Chief Operating Officer | Senior Management | - | - |
| Maud Vimeux | Chief Human Resources Officer; Senior Vice President - Human Resource | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer